Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01718743 · OUTCOME

M. D. Anderson Symptom Inventory (MDASI)-Myeloma Symptom Evaluation

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2025-01-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
scores on a scale
Interval / dispersion
Standard Deviation
Time frame
through out study treatment and up to 30 days after completion of study treatment, up to 119 months

What was measured

Analyzed with descriptive analysis. The MDASI-MM scores measure the how severe the symptoms are, so higher scores are considered to be worse patient outcomes. Five subscales are derived from the 26 questions of the MDASI-MM questionnaire: 1. mean core (13 MDASI core symptom items), ranges from 0 to 130. 2. mean severity (13 MDASI core plus 7 MM-specific items), ranges from 0 to 200. 3. mean interference (6 interference items), ranges from 0 to 60. 4. mean WAW (interference with work, general activity, and walking), ranges from 0 to 30. 5. mean REM (interference with relations with people, enjoyment of life, and mood), ranges from 0 to 30. has context menu

Groups in this outcome

Treatment (Ixazomib Citrate, Lenalidomide)

Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ixazomib Citrate: Given PO Lenalidomide: Given PO Questionnaire Administration: Ancillary studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Ixazomib Citrate, Lenalidomide)59

Reported measurements

Core Score at Cycle 1
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Treatment (Ixazomib Citrate, Lenalidomide)1.131.35Not reportedNot reportedNot reported
Severity Score at Cycle 1
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Treatment (Ixazomib Citrate, Lenalidomide)1.011.27Not reportedNot reportedNot reported
Interference Score at Cycle 1
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Treatment (Ixazomib Citrate, Lenalidomide)0.971.52Not reportedNot reportedNot reported
WAW Score at Cycle 1
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Treatment (Ixazomib Citrate, Lenalidomide)1.121.67Not reportedNot reportedNot reported
REM Score at Cycle 1
Values in scores on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Treatment (Ixazomib Citrate, Lenalidomide)0.811.54Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.35
        value
        1.13
    title
    Core Score at Cycle 1
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.27
        value
        1.01
    title
    Severity Score at Cycle 1
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.52
        value
        0.97
    title
    Interference Score at Cycle 1
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.67
        value
        1.12
    title
    WAW Score at Cycle 1
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.54
        value
        0.81
    title
    REM Score at Cycle 1
denoms
  1. counts
    1. group Id
      OG000
      value
      59
    units
    Participants
description
Analyzed with descriptive analysis. The MDASI-MM scores measure the how severe the symptoms are, so higher scores are considered to be worse patient outcomes. Five subscales are derived from the 26 questions of the MDASI-MM questionnaire: 1. mean core (13 MDASI core symptom items), ranges from 0 to 130. 2. mean severity (13 MDASI core plus 7 MM-specific items), ranges from 0 to 200. 3. mean interference (6 interference items), ranges from 0 to 60. 4. mean WAW (interference with work, general activity, and walking), ranges from 0 to 30. 5. mean REM (interference with relations with people, enjoyment of life, and mood), ranges from 0 to 30. has context menu
dispersion Type
Standard Deviation
groups
  1. description
    Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ixazomib Citrate: Given PO Lenalidomide: Given PO Questionnaire Administration: Ancillary studies
    id
    OG000
    title
    Treatment (Ixazomib Citrate, Lenalidomide)
param Type
MEAN
reporting Status
POSTED
time Frame
through out study treatment and up to 30 days after completion of study treatment, up to 119 months
title
M. D. Anderson Symptom Inventory (MDASI)-Myeloma Symptom Evaluation
type
SECONDARY
unit Of Measure
scores on a scale

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice